MX2016010871A - Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18. - Google Patents
Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.Info
- Publication number
- MX2016010871A MX2016010871A MX2016010871A MX2016010871A MX2016010871A MX 2016010871 A MX2016010871 A MX 2016010871A MX 2016010871 A MX2016010871 A MX 2016010871A MX 2016010871 A MX2016010871 A MX 2016010871A MX 2016010871 A MX2016010871 A MX 2016010871A
- Authority
- MX
- Mexico
- Prior art keywords
- dosing regimen
- fgf
- weeks
- compound dosing
- new dosing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona un nuevo régimen de dosificación para la administración de FGF18 en el tratamiento de un trastorno del cartílago tal como, por ejemplo, la osteoartritis o la lesión del cartílago; se proporciona específicamente un plan de tratamiento preferido que comprende administraciones cada 3 semanas o cada 5 semanas de un compuesto de FGF-18 por ciclo de tratamiento; el nuevo régimen de dosificación puede incluir la co-administración de un fármaco anti-inflamatorio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14000600 | 2014-02-20 | ||
| PCT/EP2015/053624 WO2015124727A1 (en) | 2014-02-20 | 2015-02-20 | Fgf-18 compound dosing regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016010871A true MX2016010871A (es) | 2016-11-17 |
Family
ID=50151088
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010872A MX2016010872A (es) | 2014-02-20 | 2015-02-20 | Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18. |
| MX2016010871A MX2016010871A (es) | 2014-02-20 | 2015-02-20 | Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010872A MX2016010872A (es) | 2014-02-20 | 2015-02-20 | Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9889179B2 (es) |
| EP (2) | EP3107559B1 (es) |
| JP (2) | JP6431082B2 (es) |
| KR (2) | KR102410986B1 (es) |
| CN (2) | CN106232622A (es) |
| AR (2) | AR099510A1 (es) |
| AU (2) | AU2015220777B2 (es) |
| BR (2) | BR112016018696A2 (es) |
| CA (1) | CA2938791A1 (es) |
| DK (2) | DK3119417T3 (es) |
| ES (2) | ES2688551T3 (es) |
| HR (2) | HRP20181572T1 (es) |
| HU (1) | HUE040350T2 (es) |
| IL (2) | IL247083B (es) |
| LT (2) | LT3107559T (es) |
| MX (2) | MX2016010872A (es) |
| NZ (1) | NZ723148A (es) |
| PL (2) | PL3119417T3 (es) |
| PT (2) | PT3107559T (es) |
| RS (2) | RS57853B1 (es) |
| RU (2) | RU2700582C2 (es) |
| SG (2) | SG11201606502YA (es) |
| SI (2) | SI3119417T1 (es) |
| WO (2) | WO2015124727A1 (es) |
| ZA (2) | ZA201605547B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3107559B1 (en) | 2014-02-20 | 2018-07-11 | Merck Patent GmbH | Fgf-18 compound dosing regimen |
| BR112016018681B1 (pt) | 2014-02-20 | 2021-01-05 | Merck Patent Gmbh | sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura |
| WO2016120387A1 (en) | 2015-01-29 | 2016-08-04 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| DK3419625T3 (da) | 2016-02-22 | 2021-07-12 | Novartis Ag | Fremgangsmåder til anvendelse af fxr-agonister |
| PL3688468T3 (pl) | 2017-09-29 | 2022-07-18 | Merck Patent Gmbh | Biomarkery stanu zapalnego do przewidywania odpowiedzi na związek fgf-18 |
| DK3687558T3 (da) | 2017-09-29 | 2022-06-20 | Merck Patent Gmbh | Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
| US20220184180A1 (en) * | 2019-02-08 | 2022-06-16 | Merck Patent Gmbh | Treatment of patients at risk of rapid progression of osteoarthritis |
| KR102920449B1 (ko) | 2023-03-29 | 2026-02-03 | 주식회사 아이프로테인테라퓨틱스 | 인터류킨-1 수용체 길항제 변이체 및 이의 용도 |
| WO2025077768A1 (en) * | 2023-10-11 | 2025-04-17 | Sichuan Real & Best Biotech Co., Ltd. | Compositions and methods for treating arthritis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136970A1 (en) * | 2002-10-07 | 2004-07-15 | Ellsworth Jeff L. | Methods for administering FGF18 |
| ES2706848T3 (es) * | 2004-07-06 | 2019-04-01 | Zymogenetics Inc | Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso |
| US20070243132A1 (en) * | 2005-12-22 | 2007-10-18 | Apollo Life Sciences Limited | Transdermal delivery of pharmaceutical agents |
| CA2658511C (en) | 2006-08-25 | 2019-02-19 | Ares Trading S.A. | Use of fgf-18 compound to treat cartilage disorders |
| ZA200900426B (en) * | 2006-08-25 | 2010-04-28 | Ares Trading Sa | Treatment of cartilage disorders with FGF-18 |
| DE102006043260A1 (de) * | 2006-09-11 | 2008-03-27 | Krones Ag | Etikettieranlage |
| EP2688890B1 (en) * | 2011-03-22 | 2017-08-30 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| EP3107559B1 (en) | 2014-02-20 | 2018-07-11 | Merck Patent GmbH | Fgf-18 compound dosing regimen |
| AU2015220781B2 (en) | 2014-02-20 | 2018-05-24 | Merck Patent Gmbh | FGF-18 in graft transplantation and tissue engineering procedures |
| BR112016018681B1 (pt) | 2014-02-20 | 2021-01-05 | Merck Patent Gmbh | sistema de distribuição de substâncias que compreende pelo menos um material polimérico formador de uma matriz e um fármaco anabólico, processo de produção do mesmo e artigo de manufatura |
-
2015
- 2015-02-20 EP EP15706006.2A patent/EP3107559B1/en active Active
- 2015-02-20 SI SI201530410T patent/SI3119417T1/sl unknown
- 2015-02-20 SG SG11201606502YA patent/SG11201606502YA/en unknown
- 2015-02-20 CN CN201580020536.2A patent/CN106232622A/zh active Pending
- 2015-02-20 AU AU2015220777A patent/AU2015220777B2/en active Active
- 2015-02-20 HR HRP20181572TT patent/HRP20181572T1/hr unknown
- 2015-02-20 PL PL15707076T patent/PL3119417T3/pl unknown
- 2015-02-20 CA CA2938791A patent/CA2938791A1/en not_active Abandoned
- 2015-02-20 LT LTEP15706006.2T patent/LT3107559T/lt unknown
- 2015-02-20 RS RS20181167A patent/RS57853B1/sr unknown
- 2015-02-20 AR ARP150100508A patent/AR099510A1/es unknown
- 2015-02-20 DK DK15707076.4T patent/DK3119417T3/en active
- 2015-02-20 ES ES15707076.4T patent/ES2688551T3/es active Active
- 2015-02-20 NZ NZ723148A patent/NZ723148A/en unknown
- 2015-02-20 AU AU2015220773A patent/AU2015220773B2/en active Active
- 2015-02-20 MX MX2016010872A patent/MX2016010872A/es active IP Right Grant
- 2015-02-20 PL PL15706006T patent/PL3107559T3/pl unknown
- 2015-02-20 WO PCT/EP2015/053624 patent/WO2015124727A1/en not_active Ceased
- 2015-02-20 SI SI201530428T patent/SI3107559T1/sl unknown
- 2015-02-20 US US15/120,131 patent/US9889179B2/en active Active
- 2015-02-20 CN CN201580020532.4A patent/CN106456713A/zh active Pending
- 2015-02-20 KR KR1020167025246A patent/KR102410986B1/ko active Active
- 2015-02-20 RU RU2016137292A patent/RU2700582C2/ru active
- 2015-02-20 DK DK15706006.2T patent/DK3107559T3/en active
- 2015-02-20 WO PCT/EP2015/053631 patent/WO2015124731A1/en not_active Ceased
- 2015-02-20 HR HRP20181570TT patent/HRP20181570T1/hr unknown
- 2015-02-20 SG SG11201606505UA patent/SG11201606505UA/en unknown
- 2015-02-20 PT PT15706006T patent/PT3107559T/pt unknown
- 2015-02-20 JP JP2016553284A patent/JP6431082B2/ja active Active
- 2015-02-20 RS RS20181168A patent/RS57709B1/sr unknown
- 2015-02-20 KR KR1020167025245A patent/KR102410988B1/ko active Active
- 2015-02-20 HU HUE15706006A patent/HUE040350T2/hu unknown
- 2015-02-20 RU RU2016137289A patent/RU2691946C2/ru active
- 2015-02-20 US US15/120,134 patent/US9724388B2/en active Active
- 2015-02-20 LT LTEP15707076.4T patent/LT3119417T/lt unknown
- 2015-02-20 ES ES15706006.2T patent/ES2689071T3/es active Active
- 2015-02-20 JP JP2016553329A patent/JP6431083B2/ja active Active
- 2015-02-20 BR BR112016018696A patent/BR112016018696A2/pt not_active Application Discontinuation
- 2015-02-20 AR ARP150100507A patent/AR099558A1/es unknown
- 2015-02-20 EP EP15707076.4A patent/EP3119417B1/en active Active
- 2015-02-20 BR BR112016018685A patent/BR112016018685A2/pt not_active Application Discontinuation
- 2015-02-20 MX MX2016010871A patent/MX2016010871A/es active IP Right Grant
- 2015-02-20 PT PT15707076T patent/PT3119417T/pt unknown
-
2016
- 2016-08-03 IL IL247083A patent/IL247083B/en active IP Right Grant
- 2016-08-03 IL IL247084A patent/IL247084B/en active IP Right Grant
- 2016-08-10 ZA ZA2016/05547A patent/ZA201605547B/en unknown
- 2016-08-10 ZA ZA2016/05548A patent/ZA201605548B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010872A (es) | Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18. | |
| TW201613859A (en) | Analogs of PRIDOPIDINE, their preparation and use | |
| LT3596222T (lt) | Raumeniui specifinis mikrodistrofino pristatymas adenoasocijuoto viruso vektoriaus dėka, skirtas raumenų distrofijai gydyti | |
| PH12017502266B1 (en) | New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| EA201890126A1 (ru) | Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| GEAP201914680A (en) | New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| GEP201706686B (en) | Novel pyrrole compounds, preparation method thereof, and pharmaceutical compositions containing them | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| IT201700026139A1 (it) | Dispositivo dosatore per l'alimentazione di un prodotto da infusione. | |
| MX2016015464A (es) | Composicion farmaceutica oral de isotretinoina. | |
| MX2020009444A (es) | Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion. | |
| JO3372B1 (ar) | مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية | |
| PH12017500853B1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| MX372682B (es) | Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico. | |
| EA201691741A1 (ru) | Фармацевтическая композиция | |
| GEAP201814266A (en) | Pyrazines modulators of gpr6 | |
| IN2014CH00840A (es) | ||
| ZA201606471B (en) | Antimitotic amides for the treatment of cancer and proliferative disorders | |
| EA201790851A1 (ru) | Способы предотвращения, уменьшения и лечения макулодистрофии | |
| SMT201800378T1 (it) | Composti di 3,4-diammino-6-cloropirazina-2-carbossammide per il trattamento di patologie enac-mediate | |
| EA202091403A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
| DK3148588T3 (en) | N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |